[Change of PML/PML-RARalpha protein during treatment with tetraarsenic tetrasulfide (As4S4) in patients with acute promyelocytic leukemia].
In order to explored the change of PML/PML-RARalpha protein during tetraarsenic tetrasulfide (As4S4) treatment, acute promyelocytic leukemia (APL) cells from a group of newly diagnosed APL patients were examined by indirect immunofluorescence staining with anit-PML monoclonal antibody. The results showed that all samples typically presented many microspeckle signals throughout the nucleus before treatment. The redistribution occurred as early as on the second day after As4S4 treatment, which revealed loss of microspeckles with the presentation of a few large speckles. Anti-PML staining also emerged in the perinuclear cytoplasm. At last, microspeckles and large speckles all disappeared. When the therapy was combining all-trans-retinoic acid (ATRA) with As4S4, similar results were obtained. However, APL cells from patients treated with ATRA alone performed totally different appearance, presenting microspeckles and large speckles at the same time, followed with entirely large speckles. The conclusion is that As4S4 makes redistribution of PML/PML-RARalpha protein in leukemic cells from APL patients during the treatment, which is quite different from that during the treatment of ATRA.
Institute of Hematology, Peking University, Beijing 100044, China.
Jing-Zhi
JZ
Wang
Yan-Rong
YR
Liu
Ya-Zhen
YZ
Qin
Hao
H
Jiang
Feng-Rong
FR
Wang
Li
L
Bao
Dao-Pei
DP
Lu
D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001152:Arsenicals / Q000627:therapeutic use*; D005260:Female; D019084:Fluorescent Antibody Technique, Indirect; D006801:Humans; D020287:In Situ Nick-End Labeling; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy* / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000032:analysis*; D009687:Nuclear Proteins; D015514:Oncogene Proteins, Fusion / Q000032:analysis*; D000071156:Promyelocytic Leukemia Protein; D014157:Transcription Factors / Q000032:analysis*; D014212:Tretinoin / Q000627:therapeutic use; D025521:Tumor Suppressor Proteins
D000970:Antineoplastic Agents; D001152:Arsenicals; D009363:Neoplasm Proteins; D009687:Nuclear Proteins; D015514:Oncogene Proteins, Fusion; D000071156:Promyelocytic Leukemia Protein; D014157:Transcription Factors; D025521:Tumor Suppressor Proteins; C093476:promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; C070576:PML protein, human; D014212:Tretinoin